SEC Tracker
Get the app

MaxCyte MXCT

MaxCyte raises 2026 revenue guidance.

Form
8-K
Filed
Importance
Routine
  1. Preliminary Q3 2026 revenue of $8.1M, up 26% YoY.
  2. SPL Program revenue of $1.0M in Q3 2026.
  3. Full-year 2026 revenue guidance raised to $34M from $30M-$32M.
  4. Core business revenue guidance raised to $28M from $25M-$27M.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when MaxCyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.

  1. NRC Health NRC public float $195M, Jun 30, 2025
  2. Absci ABSI public float $304M, Jun 30, 2025
  3. OmniAb OABI public float $145M, Jun 30, 2025
  4. Neogenomics NEO public float $680M, Jun 30, 2025
  5. Inotiv NOTV public float $71M, Mar 31, 2025, over 18 months old